Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 10:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 8,248 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Humans Clear all
Withdrawn Phase 2 Interventional

REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

NCT00715364
View directory record Official record
Conditions
Stroke
Interventions
NTx™-265: rhCG, then rEPO, Saline Placebo
Drug
Lead sponsor
Stem Cell Therapeutics Corp.
Industry
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Newport Beach, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2011 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Not applicable Interventional

Engaging Practices and Communities in the Development of Interventions to Promote HPV Vaccine Uptake

NCT04279964
View directory record Official record
Conditions
Primary Prevention
Interventions
Boot Camp Translation, Control
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
9 Years to 26 Years
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Counseling Hepatitis C Virus (HCV) Positive Patients for Cardiovascular Disease Risk Factors

NCT03402334
View directory record Official record
Conditions
Hepatitis C, Atherosclerosis
Interventions
Patient counseling for HCV associated CVD risk factors
Behavioral
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Human Anti-tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis

NCT00085644
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
adalimumab (D2E7), placebo
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
22
States / cities
Birmingham, Alabama • Mobile, Alabama • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2011 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Phase 4 Interventional

Comparative Study of Reconstituted JUVÉDERM® Ultra vs COSMODERM® 1 for Lip and Cheek Lines, Folds or Wrinkles

NCT01212809
View directory record Official record
Conditions
Intrinsic Aging of Skin
Interventions
Juvéderm Ultra, Cosmoderm 1
Device
Lead sponsor
Steven Fagien
Other
Eligibility
25 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Oct 29, 2026, 10:58 AM EDT
Terminated Phase 1 Interventional

Hemophilia B Gene Therapy With AAV8 Vector

NCT01620801
View directory record Official record
Conditions
Hemophilia B
Interventions
AAV8-hFIX19
Biological
Lead sponsor
Spark Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 29, 2026, 10:58 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Light-based Immunomodulation for Guarding Against Human Respiratory Tract Infections

NCT07610967
View directory record Official record
Conditions
COVID-19 Respiratory Infection, Influenza
Interventions
RD-X19, RD-X19 Sham
Device
Lead sponsor
David Moss
Federal
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Nellis Air Force Base, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Phase 2 Interventional

GW640385 Plus Ritonavir And NRTIs For 48 Weeks In HIV-1 Infected Adults

NCT00257621
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I, HIV Infection
Interventions
GW640385, Ritonavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
9
States / cities
Phoenix, Arizona • San Francisco, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy Adults

NCT01993706
View directory record Official record
Conditions
HIV Infection, Monoclonal Antibody, Human, HIV Antibodies, VRC01 Monoclonal Antibody, Neutralizing Antibody
Interventions
VRC-HIVMAB060-00-AB
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Infectivity of Norovirus in Groundwater-Human Challenge Study

NCT00313404
View directory record Official record
Conditions
Healthy
Interventions
Safety tested norovirus inoculum
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of the Dapivirine Vaginal Ring in Lactating Women

NCT02808949
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Dapivirine
Drug
Lead sponsor
International Partnership for Microbicides, Inc.
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII

NCT01992549
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
Human-cl rhFVIII
Biological
Lead sponsor
Octapharma
Industry
Eligibility
Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Phase 2 Interventional

Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants

NCT00130819
View directory record Official record
Conditions
Opiate Dependence, HIV Seropositivity, HIV Infections
Interventions
Clinic-based substance abuse treatment with buprenorphine, Case management and referred substance abuse treatment
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases

NCT03939533
View directory record Official record
Conditions
Primary Immune Deficiency Disorder
Interventions
CUTAQUIG
Drug
Lead sponsor
Octapharma
Industry
Eligibility
2 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
18
States / cities
Scottsdale, Arizona • Irvine, California • Santa Barbara, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Phase 1 Interventional Results available

A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors

NCT02563548
View directory record Official record
Conditions
NSCLC, Gastric Cancer
Interventions
PEGPH20, Pembrolizumab
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
28
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Encinitas, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 29, 2026, 10:58 AM EDT
Terminated Phase 1Phase 2 Interventional

Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

NCT03618134
View directory record Official record
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus Positive, Oropharyngeal Squamous Cell Carcinoma, p16 Positive Neoplastic Cells Present, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Interventions
Durvalumab, Modified Radical Neck Dissection, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy, Transoral Robotic Surgery, Tremelimumab
Biological · Procedure · Other + 1 more
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Phase 1 Interventional

Adoptive Transfer of Haploidentical Natural Killer Cells and IL-2

NCT03346499
View directory record Official record
Conditions
HIV
Interventions
NK cells and IL-2
Biological
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sensor Ankle Brace for Special Operations Rehabilitation - Phase 1

NCT07085416
View directory record Official record
Conditions
Gait, Balance, Biomechanical Data, Postural Control, Locomotion
Interventions
Sensor-enabled Athletic X Ankle Brace (sXAB)
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute Influenza

NCT00705406
View directory record Official record
Conditions
Acute, Uncomplicated Human Influenza
Interventions
Peramivir, Placebo
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
67
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Phase 1 Interventional

Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis

NCT03231033
View directory record Official record
Conditions
Autoimmune Pulmonary Alveolar Proteinosis
Interventions
Pioglitazone
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 29, 2026, 10:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Increasing Vaccine Uptake Among Adolescents in the Rural South

NCT04999267
View directory record Official record
Conditions
Vaccine Hesitancy
Interventions
INVEST
Other
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Durham, North Carolina • Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 29, 2026, 10:58 AM EDT
Not listed No phase listed Observational

Enhanced Assisted Reproductive Technology Pregnancy Rate by Prostacyclin Analog (Iloprost)

NCT01549171
View directory record Official record
Conditions
Pregnancy
Interventions
Iloprost, normal saline
Drug · Other
Lead sponsor
Fertility Specialists of Houston
Other
Eligibility
20 Years to 39 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 29, 2026, 10:58 AM EDT
Terminated Phase 4 Interventional Results available

DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant

NCT03208244
View directory record Official record
Conditions
End Stage Heart Disease, Hepatitis C
Interventions
Clinically prescribed direct acting antiviral
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 29, 2026, 10:58 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

NCT07169734
View directory record Official record
Conditions
Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma, Urothelial Carcinoma
Interventions
ALE.P03
Drug
Lead sponsor
Alentis Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 29, 2026, 10:58 AM EDT